Loading...
Home 2019-03-01T13:18:24+00:00

Outlook Therapeutics Submits IND Application for ONS-5010 to the FDA

Outlook Therapeutics Provides Business Update and Reports Q1 Financial Results

Outlook Therapeutics…

…is a late clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a complex, technically challenging and commercially attractive monoclonal antibody, for various ophthalmic indications..

ABOUT ONS-5010

ONS-5010 is a proprietary ophthalmic formulation of bevacizumab to be administered as an intravitreal injection for the treatment of wet AMD and other retina diseases.